CClinicalTrials.gg
CompletedNCT07829666Updated Sep 21, 2026

Short-Term Effects of Low-FODMAP, NICE Dietary Advice, and Intermittent Fasting in Irritable Bowel Syndrome

An interventional study of Low-FODMAP Diet and Adapted NICE Dietary Advice in Irritable Bowel Syndrome, sponsored by Acibadem University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Acibadem University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the short-term effects of three dietary approaches in adults with irritable bowel syndrome (IBS): a low-FODMAP diet, adapted National Institute for Health and Care Excellence (NICE) dietary advice, and adapted NICE dietary advice combined with 16:8 intermittent fasting.

The main questions this study aims to answer are:

How do these three dietary approaches affect IBS symptom severity after two weeks? How do these three dietary approaches affect IBS-related quality of life after two weeks? The researchers hypothesize that the low-FODMAP diet will produce the greatest short-term reduction in IBS symptom severity. The study will also explore whether adding 16:8 intermittent fasting to adapted NICE dietary advice provides additional benefit.

Researchers will compare the three dietary groups to determine whether the changes in IBS symptoms and quality of life differ between the dietary approaches.

Participants will:

Follow one of the three dietary approaches for two weeks. Attend study visits at the beginning of the study, after one week, and after two weeks.

Keep records of their food and fluid intake. Complete questionnaires about IBS symptoms, quality of life, anxiety, and depression.

Record their stool form and frequency during the study.

02

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • Low-FODMAP Diet
  • NICE Dietary Advice
  • Intermittent Fasting
  • 16:8 Intermittent Fasting
  • Irritable Bowel Syndrome
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Adults aged 18-65 years Diagnosis of irritable bowel syndrome (IBS) according to the Rome IV criteria IBS subtype classified as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), or IBS with mixed bowel habits (IBS-M)

Exclusion criteria

Exclusion Criteria:

Celiac disease Inflammatory bowel disease History of cancer Diabetes Kidney disease Pregnancy Current adherence to an elimination diet

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Low-FODMAP Diet (LF)

    Participants in this arm followed a researcher-designed low-FODMAP elimination diet for two weeks. The dietary intervention was delivered by a dietitian who had completed Monash University Low-FODMAP Diet Training.

    Behavioral: Low-FODMAP Diet

  • Active comparator
    Adapted NICE Dietary Advice (NICE)

    Participants in this arm followed adapted NICE dietary advice for two weeks. The recommendations included eating regular meals and avoiding prolonged fasting, drinking at least 2 liters of water per day, limiting fruit intake to a maximum of three servings (240 g) per day, limiting tea and coffee to a maximum of three cups per day, and limiting alcohol and carbonated beverages. No specific restriction on fiber or FODMAP intake was applied.

    Behavioral: Adapted NICE Dietary Advice

  • Active comparator
    Adapted NICE Dietary Advice Plus Intermittent Fasting (NICE-IF)

    Participants in this arm followed adapted NICE dietary advice combined with a 16:8 intermittent fasting regimen for two weeks. All meals were consumed within an 8-hour eating window, either from 11:00 to 19:00 or from 12:00 to 20:00, followed by a 16-hour fasting period. One or two snacks were permitted within the eating window. No specific restriction on fiber or FODMAP intake was applied.

    Behavioral: 16:8 Intermittent Fasting

Interventions

  • BehavioralLow-FODMAP Diet

    Participants followed a researcher-designed low-FODMAP elimination diet for two weeks. The dietary intervention was delivered by a dietitian who had completed Monash University Low-FODMAP Diet Training. Foods containing fermentable oligosaccharides, lactose, excess fructose, and polyols were restricted. The reintroduction phase of the low-FODMAP diet was not implemented during the two-week study period.

  • BehavioralAdapted NICE Dietary Advice

    Participants followed adapted NICE dietary advice for two weeks. The recommendations included eating regular meals and avoiding prolonged fasting, drinking at least 2 liters of water per day, limiting

  • Behavioral16:8 Intermittent Fasting

    Participants followed a 16:8 intermittent fasting regimen in addition to adapted NICE dietary advice for two weeks. All meals were consumed within an 8-hour eating window, either from 11:00 to 19:00 or from 12:00 to 20:00, followed by a 16-hour fasting period. One or two snacks were permitted within the eating window. No specific restriction on fiber or FODMAP intake was applied.

05

What researchers measure

Primary outcomes

  1. Change in Irritable Bowel Syndrome Symptom Severity

    IBS symptom severity was assessed using the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS). The total score ranges from 0 to 500, with higher scores indicating greater symptom severity. A reduction of at least 50 points was considered a clinically meaningful improvement.

    Time frame: Baseline to 2 weeks

Secondary outcomes

  1. Change in Irritable Bowel Syndrome-Specific Quality of Life

    IBS-specific quality of life was assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL). The questionnaire consists of 34 items across eight subscales. Scores are transformed to a 0-100 scale, with higher scores indicating better IBS-specific quality of life.

    Time frame: Baseline to 2 weeks

06

Study locations

1 site
  • Acibadem Kozyatagi Hospital
    Istanbul, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07829666
Lead sponsor
Acibadem University
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Feb 1, 2024
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Sep 21, 2026

Study contacts

Nur E Baydı Ozman, PhD
principal investigator · Acibadem Atasehir Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion